The group of tumors known as tenosynovial giant cell tumors (TGCT) are classified based on their growth patterns and the specific joints they involve. These tumors generally originate in the synovial tissue, which lines joints and tendons, leading to distinct forms with varying behaviors and affected areas. The two main types are considered distinct in their presentation, progression, and treatment approaches: localized and diffuse forms.

Understanding the Different Types of Tenosynovial Giant Cell Tumors

The localized form of TGCT, often called giant cell tumor of the tendon sheath, primarily develops in small joints such as those in the fingers, hands, or wrists. These tumors tend to grow slowly and are usually benign, meaning they don't tend to invade surrounding tissues aggressively. They often present as a discrete, palpable lump that might cause discomfort or minor functional impairment but rarely pose serious health threats if treated promptly.

In contrast, the diffuse form, known as pigmented villonodular synovitis (PVNS), is more aggressive. It typically affects larger joints such as the knees, hips, ankles, elbows, or shoulders. PVNS progresses more rapidly and often invades adjacent tissues, which can lead to joint destruction if left untreated. Unlike localized tumors, diffuse PVNS can sometimes extend outside the joint capsule, affecting surrounding structures and complicating treatment plans.

Both tumor types may involve intra-articular regions—inside the joint cavity—and in some cases, can be found outside the joint space (extra-articular). Rarely, these tumors can metastasize to distant sites like the lungs or lymph nodes, highlighting the importance of early detection and management.

Origins and Causes of Tenosynovial Giant Cell Tumors

The root cause of TGCTs is linked to chromosomal alterations. Specifically, a chromosomal translocation—a genetic mutation where segments of chromosomes break off and attach to other chromosomes—has been identified as a key factor. While the precise triggers of this translocation remain unclear, its presence is confirmed in most cases.

This translocation affects the genetic instructions that cells use to produce proteins, leading to abnormal expression levels of certain proteins. One critical protein involved is colony-stimulating factor 1 (CSF1). Overproduction of CSF1 results in the attraction of cells bearing CSF1 receptors, notably macrophages—white blood cells responsible for immune defense. These cells accumulate and proliferate, forming the tumor mass characteristic of TGCT.

The condition predominantly affects individuals in their 30s and 40s, with some variation depending on the tumor type and location. Although it’s not inherited genetically, the chromosomal abnormality is considered a mutation rather than a hereditary trait.

Recognizing the Symptoms of Tenosynovial Giant Cell Tumor

Early detection of TGCT can significantly improve treatment outcomes. Recognizing the symptoms is vital for timely medical intervention. The most common signs include:

• Joint stiffness, often affecting mobility and comfort
• The presence of a noticeable lump or swelling around the affected joint
• Pain or tenderness in the joint area, which may worsen with activity
• Warmth or redness of the skin over the joint, indicating inflammation
• Audible or felt sounds such as locking, popping, or catching during joint movement, signaling mechanical interference

If these symptoms are observed, consulting an orthopedic specialist as soon as possible is crucial. Without intervention, these tumors may enlarge, cause joint damage, or lead to loss of function.